Google DeepMind's Isomorphic Labs Nears Human Trials for AI-Designed Drugs

Reviewed byNidhi Govil

4 Sources

Isomorphic Labs, a subsidiary of Alphabet's Google DeepMind, is preparing to begin human clinical trials for drugs designed using artificial intelligence, marking a significant milestone in AI-powered drug discovery.

Isomorphic Labs Prepares for Groundbreaking Human Trials

Isomorphic Labs, a subsidiary of Alphabet's Google DeepMind, is on the brink of a significant milestone in the field of AI-powered drug discovery. Colin Murdoch, President of Isomorphic Labs and Chief Business Officer of Google DeepMind, has announced that the company is "getting very close" to initiating human clinical trials for drugs designed using artificial intelligence 1.

Source: Fortune

Source: Fortune

The Journey from AlphaFold to Human Trials

Isomorphic Labs was spun out of DeepMind in 2021, building upon the success of AlphaFold, an AI system capable of predicting protein structures with high accuracy. The evolution of AlphaFold has been crucial in advancing drug discovery capabilities:

  1. Initially predicting individual protein structures
  2. Progressing to modeling protein interactions with other molecules like DNA and drugs
  3. Culminating in the release of AlphaFold 3 in 2024 1

This progression has significantly enhanced the speed and precision of drug design, serving as the foundation for Isomorphic Labs' ambitious goals.

Source: Digit

Source: Digit

Building a "World-Class Drug Design Engine"

Isomorphic Labs aims to revolutionize the pharmaceutical industry by:

  1. Accelerating drug development processes
  2. Reducing costs associated with drug discovery
  3. Improving the success rate of drug candidates 3

The company has made significant strides in achieving these objectives:

  • Signed major research collaborations with Novartis and Eli Lilly in 2024
  • Raised $600 million in external funding in April 2025, led by Thrive Capital 1

AI-Powered Drug Discovery: A New Frontier

Traditional drug development is often a lengthy, expensive process with a high failure rate. Isomorphic Labs believes its AI-driven approach can dramatically improve these odds. The company is developing its own internal drug candidates in areas such as oncology and immunology, with plans to license them out after early-stage trials 4.

Murdoch envisions a future where researchers can input a disease and have an AI system design an appropriate drug at the click of a button 1.

The Competitive Landscape

As Isomorphic Labs prepares for human trials, other players in the field are also making significant progress:

  • Recursion Pharmaceuticals expects seven programs to begin or conclude human studies next year
  • Insilico Medicine has reported positive results from trials of its AI-designed drug for inflammatory bowel disease
  • AMD has invested $20 million in Absci to challenge Nvidia's BioNeMo platform in AI drug discovery 3
Source: Fast Company

Source: Fast Company

The Road Ahead

As Isomorphic Labs prepares for this crucial phase, the scientific community and investors alike are watching closely. The success of these trials could mark a turning point in drug development, potentially leading to faster, more efficient, and more successful creation of new medicines 2.

Explore today's top stories

OpenAI Launches ChatGPT Study Mode: A New Approach to AI-Assisted Learning

OpenAI introduces Study Mode for ChatGPT, designed to enhance learning experiences by encouraging critical thinking rather than providing direct answers. This new feature aims to address concerns about AI's impact on education and student learning.

Ars Technica logoTechCrunch logoMIT Technology Review logo

20 Sources

Technology

11 hrs ago

OpenAI Launches ChatGPT Study Mode: A New Approach to

Microsoft and OpenAI in Advanced Talks to Reshape AI Partnership Amid Cloud Competition

Microsoft and OpenAI are negotiating a new deal that could ensure Microsoft's continued access to OpenAI's technology, even after achieving AGI. This comes as OpenAI diversifies its cloud partnerships, potentially challenging Microsoft's AI edge.

Bloomberg Business logoReuters logoEconomic Times logo

11 Sources

Technology

19 hrs ago

Microsoft and OpenAI in Advanced Talks to Reshape AI

Anthropic Nears $170 Billion Valuation in Potential $5 Billion Funding Round

Anthropic, the AI startup, is close to securing a massive funding round led by Iconiq Capital, potentially valuing the company at $170 billion. This development highlights the growing investor interest in AI companies and the increasing involvement of Middle Eastern capital in the sector.

TechCrunch logoBloomberg Business logoCNBC logo

4 Sources

Business and Economy

10 hrs ago

Anthropic Nears $170 Billion Valuation in Potential $5

Meta's Aggressive AI Talent Hunt and Superintelligence Push: High Costs, Uncertain Returns

Meta CEO Mark Zuckerberg's ambitious pursuit of AI talent and superintelligence capabilities faces challenges as the company reports slower growth amid rising costs. The tech giant's strategy includes massive investments in AI infrastructure and high-profile hires, but questions remain about its open-source approach and the performance of its Llama 4 model.

Wired logoReuters logoCNBC logo

7 Sources

Technology

11 hrs ago

Meta's Aggressive AI Talent Hunt and Superintelligence

Google Enhances AI Mode with New Features for Students and Researchers

Google introduces new AI Mode features including Canvas for study planning, image and PDF uploads on desktop, and real-time video input for Search Live, aimed at improving research and learning experiences.

TechCrunch logoThe Verge logoengadget logo

11 Sources

Technology

11 hrs ago

Google Enhances AI Mode with New Features for Students and
TheOutpost.ai

Your Daily Dose of Curated AI News

Don’t drown in AI news. We cut through the noise - filtering, ranking and summarizing the most important AI news, breakthroughs and research daily. Spend less time searching for the latest in AI and get straight to action.

© 2025 Triveous Technologies Private Limited
Instagram logo
LinkedIn logo